Danish Biotech Stock News

Novo Nordisk stock is back under the microscope after a weak three year share price run, even as its valuation checks screen it as attractively priced on several fronts. Recent setbacks in parts of the drug pipeline have weighed on sentiment, while strong demand for obesity treatments keeps investors focused on what the current price actually implies. The share price has fallen 46.9% over the past three years, which means anyone buying today is doing so after a sizeable reset in market...

What Ørsted’s Old 300 Storage milestone means for the stock Ørsted (CPSE:ORSTED) has brought its Old 300 Storage battery project in Needville, Texas, into commercial operation, connecting 250 MW of storage capacity to the ERCOT grid alongside the existing Old 300 Solar facility. This expansion in U.S. battery energy storage, supplied by Tesla Megapacks and paired with one of the larger U.S. solar projects commissioned in 2024, gives investors fresh context for assessing Ørsted’s role in large...

The market has treated Genmab like a growth biotech with questions attached. The stock sits at DKK2,011 after a strong 90 day run of about 23%, and today’s Q2 print gives investors fresh numbers to test that view. The headline is simple. Genmab just delivered Q2 2026 total revenue of US$1.16b with net income of US$303m and basic earnings per share of US$4.94. That is the core of the story investors will weigh against a higher than peer P/E multiple and the company’s ambitious late stage...

Vestas Wind Systems (CPSE:VWS) has drawn fresh investor attention after appointing Anna Mascolo as President of Northern & Central Europe and Global Offshore, following the retirement of long-serving regional leader Nils de Baar. See our latest analysis for Vestas Wind Systems. The leadership change appears to have come at a time when Vestas Wind Systems' short term momentum has cooled, with a 90 day share price return that declined 9.55%, even as the 1 year total shareholder return is...

As the European market continues to show resilience, with indices like the STOXX Europe 600 hitting new highs driven by robust corporate earnings and a recovery in AI-related stocks, investors are keenly observing growth opportunities. In this environment, companies with high insider ownership can be particularly appealing as they often indicate strong confidence from those most familiar with the business's potential.

Novo Nordisk (CPSE:NOVO B) obtained a Dutch court injunction to block a compounding pharmacy from offering an unapproved semaglutide nasal spray. The ruling protects Novo Nordisk's semaglutide patents and limits compounded GLP-1 drug products that fall outside approved uses in Europe. The decision supports the exclusivity of branded therapies Wegovy, Ozempic and Rybelsus at a time of strong market interest in obesity and diabetes treatments. The case highlights how patent enforcement and...

ALK-Abelló (CPSE:ALK B) shares are in focus after the company reported that neffy, its epinephrine nasal spray for emergency treatment of anaphylaxis, is now available across Canada following Health Canada approval earlier this year. See our latest analysis for ALK-Abelló. The neffy launch comes after a strong period for ALK-Abelló, with the stock posting a 1-year total shareholder return of 20.15%, even as the 90-day share price return declined 13.69% and the year-to-date share price return...

Føroya Banki walked into this earnings print wearing a value label, trading on a trailing P/E of 10.2x against a richer European banks peer group. The stock closed yesterday at DKK277.5 and had quietly built a double digit 90 day gain, which indicates expectations were warming up again. The headline from Q2 is clear for a regional lender. Earnings per share of 7.26 DKK and net income of DKK69.5m sat on top of a cost base that already looked lean in earlier quarters. The key question now is...

Ringkjøbing Landbobank stock came into today priced for quality, trading at DKK1,770 with a P/E of 18.2x that sits above both European banking peers and the wider sector. The headline from Q2 is earnings power that still holds up. Net income for the quarter landed at DKK608.3m and basic earnings per share reached DKK26.01, while trailing 12 month profit margin stayed high at 55.3%. The short term move is about whether that premium valuation still feels comfortable. The longer term story is...

Novo Nordisk heads into this earnings reaction as a stock that has cooled off in the short term, with the share price down about 13% over the past week and 8% over the past month, even as many investors still view it as a long term growth engine in weight loss and diabetes. The Q2 headline is simple: solid demand for obesity and diabetes drugs translated into DKK 78,488m of revenue, yet profit was squeezed, with gross margin falling to 78.2% and net income at DKK 20,989m. Is Novo Nordisk...

Investeringsselskabet af 3. November 2025 A/S' (CPH:3NOV25) stock rose 17% last week, but insiders who sold kr.4.3m...

Jyske Bank (CPSE:JYSK) has launched a share repurchase programme running from 5 February 2026 to 29 January 2027, authorising buybacks of up to DKK 3b under EU market abuse rules. See our latest analysis for Jyske Bank. Jyske Bank's latest share repurchase announcement lands after a strong run, with the current share price at DKK 1,037.0, a 30 day share price return of 6.91% and a 1 year total shareholder return of 62.19%. This points to solid momentum supported by improving sentiment around...

In July 2026, Genmab A/S and AbbVie clarified that the Phase 3 EPCORE DLBCL-1 trial of epcoritamab in relapsed or refractory diffuse large B-cell lymphoma did not achieve a statistically significant improvement in overall survival, the sole primary endpoint in the United States. This clarification highlights the complexity of region-specific trial endpoints and leaves investors waiting for detailed peer-reviewed data to understand epcoritamab’s broader clinical profile. We’ll now examine how...

Why the EPCORE DLBCL-1 Update Matters for Genmab Stock Genmab (CPSE:GMAB) is back in focus after the company and partner AbbVie clarified that the Phase 3 EPCORE DLBCL-1 trial for epcoritamab did not achieve its overall survival primary endpoint in the United States. See our latest analysis for Genmab. At a share price of DKK1,858.5, Genmab has recently seen a 30 day share price return of 3.25% and a 90 day share price return of 9.71%. The 1 year total shareholder return of 33.99% contrasts...

In recent weeks, global markets have been navigating a complex landscape marked by rising oil prices, geopolitical tensions in the Middle East, and fluctuating investor sentiment around AI investments. Amid these challenges, major indices like the Nasdaq Composite and S&P 500 have faced declines, while European markets showed resilience with modest gains. In such an environment, identifying undervalued stocks can be crucial for investors seeking opportunities that may offer potential...

Danske Bank (CPSE:DANSKE) is back in focus after raising its 2026 net profit guidance to DKK 23b to DKK 25b and targeting around 14% return on equity, alongside fresh second quarter earnings. See our latest analysis for Danske Bank. At a share price of DKK362.4, Danske Bank has seen its 1 month share price return of 5.13% build on a 3 month gain of 10.02%. The 1 year total shareholder return of 52.45% and 5 year total shareholder return of 355.31% point to strong longer term momentum around...

Novo Nordisk (CPSE:NOVO B) is back in focus after European regulators cleared its once daily Wegovy pill, and Crux announced a US employer-focused collaboration to widen access to its anti obesity medications. See our latest analysis for Novo Nordisk. These Wegovy updates have landed while Novo Nordisk’s stock has shown strong recent momentum, with a 90 day share price return of 23.14% but a weaker 1 year total shareholder return, which is down 24.28%. If this obesity and diabetes story has...

Demant (CPSE:DEMANT) has launched a new cosmetic hearing aid that aims to strengthen its position in hearing healthcare at a time when competition from Sonova is intensifying in the largest hearing aid category. See our latest analysis for Demant. Against this product launch backdrop, Demant's share price has gained 39.2% over the past 90 days and 30.46% year to date to DKK278.4. Longer term total shareholder returns have been modest, including a 3% return over three years and a 28.06%...

Rising trade tensions between China and the EU, a China EU trade surplus up 24% year on year in the first half, and talk of tougher tariffs are putting supply chains and export heavy business models under fresh scrutiny. For investors, this sharpens the focus on European reshoring and nearshoring, where production and sourcing sit closer to end markets rather than relying heavily on China. This article looks at 3 stocks from a European Industrial Reshoring screener that are directly exposed...

European supply chains are being reshaped as the China EU trade surplus climbs 24% year on year in 2024 and Brussels pushes for “tangible results” by October. For investors, that tension can create both risks and openings, especially where reshoring, nearshoring, and diversification themes intersect with listed stocks. This article focuses on three European companies from manufacturing, logistics, and technology that are exposed to the latest China EU trade headlines, and that could stand to...

DSV earnings and humanitarian activity draw investor focus DSV (CPSE:DSV) is in the spotlight after reporting second quarter 2026 results that combined higher sales with slightly lower net income, alongside participation in a large humanitarian airlift to earthquake hit communities in Venezuela. See our latest analysis for DSV. Despite the latest earnings and humanitarian airlift drawing attention, DSV's 1 year total shareholder return is down 6.44% and its share price is down 9.47% year to...

It's been a sad week for DSV A/S ( CPH:DSV ), who've watched their investment drop 14% to kr.1,449 in the week since...

Novo Nordisk recently sued Eli Lilly in a U.S. federal court, alleging that Lilly’s television and digital ads for Zepbound and Mounjaro use outdated clinical data and unfair dosing comparisons to overstate their advantages versus Wegovy and Ozempic in obesity and diabetes treatment. The case puts drug marketing standards for GLP‑1 therapies under the spotlight, with the outcome potentially influencing how companies communicate head‑to‑head efficacy in a highly competitive, high-stakes...

A.P. Møller - Mærsk (CPSE:MAERSK B) stock is in focus after the company committed $100 million to a new 617,000-square-foot fulfillment hub near Boston, tailored for a single large e-commerce customer. See our latest analysis for A.P. Møller - Mærsk. This logistics expansion comes as A.P. Møller - Mærsk’s share price shows solid momentum, with a 30 day share price return of 6.41% and a year to date share price return of 16.47%, alongside a 1 year total shareholder return of 29.52% that...